Do We Need Another Selective Estrogen Receptor Modulator for the Adjuvant Treatment of Breast Cancer?

T. Shenkier

doi:10.3747/co.20.1466

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Editorial

1 August 2013

Do We Need Another Selective Estrogen Receptor Modulator for the Adjuvant Treatment of Breast Cancer?

Tamara Shenkier, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada

Curr. Oncol.2013, 20(4), 191-192;https://doi.org/10.3747/co.20.1466

Version Notes

Order Reprints

Abstract

In this issue of Current Oncology, Qin and colleagues from the Sun Yat-sen University Cancer Centre in Guangzhou, China, report their experience using toremifene as adjuvant treatment for 396 premenopausal women with early endocrine-responsive breast cancer at a mean follow-up of 6.9 years. [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Corrigendum: Ubiquitin Pathway and Ovarian Cancer

hpv is Here to Stay